Skip to main content
. 2020 Jan 7;11(1):31–45. doi: 10.18632/oncotarget.27414

Figure 7. Classification of anti-HER3 mAbs, and in vivo anti-tumor effects of anti-HER3 mAb on colon cancer cells in nude mice.

Figure 7

(A) PCA by the binding inhibition analyses of anti-HER3 mAbs. (B) PCA by the amino acid identity of CDR of anti-HER3 mAbs. (C) Correlation diagram about seven anti-HER3 mAbs between %CDR homology and binding inhibition (%). (D) Summary table showing various features of seven anti-HER3 mAbs. (E) In vitro ffects of anti-HER3 mAb (Ab4) or patritumab on the cell growth of MCF7 cells with or without Erlotinib. (F) Anti-tumor effects of anti-HER3 mAb (Ab4) or patritumab on BT474 human breast cancer cells were evaluated (n = 4). Anti-tumor effects of anti-HER3 mAb (Ab4) on LS-174T (G, n = 3) and LS-LM4 (H, n = 8) human colon cancer cells were evaluated.